🔍

INNOVACAP - Innova Captab

📊 NSE: INNOVACAP 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:06

📢 Recent Corporate Announcements

Innova Captab to Attend Investec Promoter & Founder Conference on March 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Mar 2026, 03:17 PM

Innova Captab Limited has scheduled a physical meeting with institutional investors and analysts on March 9, 2026. The interaction will take place at the Investec Promoter & Founder Conference 2026 in Mumbai, starting from 10:00 AM IST. The company will engage in both 1x1 and group meeting formats to discuss business updates. Management has clarified that no unpublished price sensitive information (UPSI) will be shared during these sessions.

Meeting scheduled for March 9, 2026, starting at 10:00 AM IST in Mumbai.
Participation in the Investec Promoter & Founder Conference 2026.
Interaction format includes both 1x1 and group meetings with investors.
Discussions will be strictly based on publicly available information.

💡 No immediate action is required as this is a routine investor engagement. Investors may monitor for any subsequent investor presentations or transcripts that could provide additional qualitative insights into the company's strategy.

Innova Captab to Host Institutional Investor Visit to Kathua Facility on Feb 27, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 06:35 PM

Innova Captab Limited has scheduled a physical visit for analysts and institutional investors to its manufacturing facility in Kathua, Jammu & Kashmir. The event is set for February 27, 2026, starting at 08:00 AM IST. The company clarified that discussions will be limited to publicly available information and no unpublished price sensitive information (UPSI) will be shared. This visit allows institutional players to gain firsthand insight into the company's operational capabilities and infrastructure.

Scheduled a physical site visit for analysts and institutional investors on February 27, 2026
The visit will take place at the company's manufacturing facility located in Kathua, Jammu & Kashmir
The session is scheduled to begin at 08:00 AM IST and will involve interactions based on public data
Company explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the visit

💡 Investors should monitor for any post-visit reports from participating brokerage houses that might provide qualitative insights into the company's production efficiency. No immediate action is required as the meeting will not disclose price-sensitive information.

Innova Captab to Participate in Systematix India Annual Conference on February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 04:57 PM

Innova Captab Limited has scheduled an interaction with institutional investors and analysts on February 9, 2026. The company will be attending the 'Manthan – Systematix India Annual Conference 2026' in Mumbai. The meetings are set to begin at 10:00 AM IST and will be conducted in both 1x1 and group formats. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in Manthan – Systematix India Annual Conference scheduled for February 9, 2026.
Meetings will be held in physical mode in Mumbai starting from 10:00 AM IST.
Format includes both 1x1 and group meetings with various institutional investors.
Company confirms discussions will be restricted to publicly available information only.

💡 Investors should monitor the exchange filings for any investor presentations that may be released alongside this conference. This is a routine engagement and does not require immediate portfolio changes.

Innova Captab Q3 FY26 Revenue Surges 42% to ₹450 Cr; Branded Generics Grow 79%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 04:47 PM

Innova Captab reported a strong Q3 FY26 with consolidated revenue growing 42.3% YoY to ₹450.3 crores, driven by a massive 79% surge in the branded generics segment. The CDMO business also showed steady growth of 29% YoY, contributing ₹298.7 crores to the top line. The newly commissioned Jammu facility is scaling up well, contributing ₹89 crores this quarter and nearing EBITDA break-even. Profitability remained robust with EBITDA rising 39.6% to ₹71.1 crores, maintaining a healthy margin of 15.8%.

Consolidated Q3 revenue reached ₹450.3 crores, a 42.3% YoY increase from ₹316.4 crores.
Branded generics segment grew 79% YoY to ₹151.6 crores due to aggressive domestic and international expansion.
Jammu facility revenue rose to ₹89 crores from ₹60 crores in the previous quarter, nearing EBITDA break-even.
EBITDA increased by 39.6% YoY to ₹71.1 crores with margins steady at 15.8%.
Exports formed 35% of Q3 revenue mix, supported by new UK-MHRA and PIC/S certifications.

💡 Investors should monitor the ramp-up of the Jammu facility, which has a potential revenue capacity of ₹1,400+ crores at optimum utilization. The strong growth in high-margin branded generics and expansion into regulated export markets provides a positive long-term outlook.

Innova Captab Declares ₹2 Interim Dividend; Sets January 30 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 Jan 2026, 06:24 PM

Innova Captab Limited has declared an interim dividend of ₹2 per equity share, representing 20% of the face value of ₹10 each for FY 2025-26. The company has fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. In compliance with the Finance Act 2020, the dividend is taxable, and the company will deduct Tax at Source (TDS) based on the residential status and documentation provided by shareholders. Shareholders are required to submit relevant tax forms by 5:00 PM on the record date to ensure appropriate tax treatment.

Interim dividend declared at ₹2 per equity share (20% of face value).
Record date for dividend eligibility is fixed as Friday, January 30, 2026.
TDS will be deducted based on documentation submitted via KFintech portal by Jan 30.
Dividend payments will be made exclusively through electronic modes like NEFT and RTGS.
The board meeting declaring this dividend was held on January 23, 2026.

💡 Investors should ensure their bank account details are updated with their DP and submit Form 15G/15H by January 30 to minimize TDS impact.

Innova Captab Releases Audio Recording of Q3 & 9M FY26 Earnings Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 27 Jan 2026, 06:06 PM

Innova Captab Limited has officially released the audio recording of its earnings conference call held on January 27, 2026. The call addressed the company's unaudited financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI Listing Regulations to ensure all investors have access to management commentary. The recording provides insights into the operational and financial trajectory of the company during the third quarter of the 2026 fiscal year.

Audio recording for the Q3 and 9M FY26 earnings call is now available on the company website.
The earnings call was conducted via digital means on January 27, 2026, at 12:00 Noon IST.
The filing complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The recording link is hosted under the 'Audio Recording' section of www.innovacaptab.com.

💡 Investors should listen to the recording to understand management's outlook on growth and margins for the remainder of FY26.

Innova Captab Q3 FY26 Revenue Surges 42% YoY to ₹450 Cr; Branded Generics Up 79%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 04:29 PM

Innova Captab reported a strong Q3 FY26 with revenue growing 42.3% YoY to ₹450.3 crore, driven by a massive 79% jump in the Branded Generics segment. EBITDA increased by 39.6% to ₹71.1 crore, though margins slightly contracted to 15.8% from 16.1% due to higher employee and material costs. The company achieved significant regulatory milestones, including UK-MHRA and PIC/s GMP certifications, which are expected to boost international market access. The newly commercialized Jammu facility is ramping up, providing a long-term growth runway with significant tax incentives.

Consolidated Revenue for Q3 FY26 grew 42.3% YoY to ₹450.3 crore, while 9M FY26 revenue reached ₹1,182.2 crore.
Branded Generics segment showed stellar performance with 79% YoY growth in Q3, reaching ₹151.6 crore.
EBITDA for the quarter rose 39.6% to ₹71.1 crore, maintaining a healthy margin of 15.8%.
Export contribution increased to 35% of total revenue in Q3 FY26, supported by new global GMP certifications.
The Jammu manufacturing facility, commercialized in Jan 2025, is eligible for GST-linked incentives totaling 300% of investment over 10 years.

💡 Investors should monitor the capacity utilization ramp-up at the Jammu facility and the margin trajectory as the high-growth Branded Generics business scales. The stock remains a strong play on the Indian CDMO and generic export themes.

Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹450.3 Cr; PAT Rises 23%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 02:59 PM

Innova Captab Limited delivered a robust performance in Q3 FY26, with revenue from operations surging 42.3% YoY to ₹450.3 crores. EBITDA followed suit with a 39.6% increase to ₹71.1 crores, although margins contracted slightly by 30 bps to 15.8%. The company reported a 23.2% growth in PAT for the quarter, reaching ₹42.1 crores. Additionally, the receipt of UK-MHRA and PIC/s certifications for its manufacturing units strengthens its international market prospects.

Q3 FY26 Revenue from operations grew 42.3% YoY to ₹450.3 crores.
EBITDA for the quarter increased 39.6% YoY to ₹71.1 crores with a 15.8% margin.
Profit After Tax (PAT) for Q3 FY26 rose 23.2% YoY to ₹42.1 crores.
Received UK-MHRA GMP certification for Baddi unit and PIC/s compliance for Jammu facility.
9M FY26 Revenue reached ₹1182.2 crores, up 27.3% compared to 9M FY25.

💡 The strong top-line growth and new global regulatory approvals suggest a positive outlook for the CDMO and export business. Investors should maintain a positive stance while monitoring if the company can improve its margins in upcoming quarters.

Innova Captab Q3 Profit Jumps 23% to ₹421.5 Mn; Declares ₹2 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 01:14 PM

Innova Captab reported a strong 42.3% YoY increase in consolidated revenue to ₹4,502.93 million for Q3 FY26. Net profit for the quarter rose 23.2% to ₹421.49 million, while basic EPS improved to ₹7.37 from ₹5.97. The company also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. For the nine-month period ending December 2025, revenue reached ₹11,822.16 million with a total profit of ₹1,028.34 million.

Consolidated revenue increased by 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Consolidated net profit grew 23.2% YoY to ₹421.49 million for the quarter.
Declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26.
9M FY26 revenue reached ₹11,822.16 million, up from ₹9,289.35 million in 9M FY25.
Fixed January 30, 2026, as the record date for determining dividend eligibility.

💡 The strong revenue growth and consistent dividend payout reflect positive operational momentum in the pharmaceutical segment. Investors may consider holding or accumulating on dips, given the double-digit profit growth and healthy cash distribution.

Innova Captab Q3 PAT Rises 23% YoY to ₹42.1 Cr; Declares ₹2 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 01:11 PM

Innova Captab Limited reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, showing significant recovery from the previous quarter's ₹296.70 million. The Board has declared an interim dividend of ₹2 per equity share (20% of face value). The record date for the dividend is fixed as January 30, 2026, with the company maintaining a healthy growth trajectory across its pharmaceutical segments.

Consolidated Revenue from operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million in Q3 FY26.
Interim Dividend of ₹2 per share declared with a Record Date of January 30, 2026.
Quarter-on-Quarter PAT saw a sharp rise of 42.1% from ₹296.70 million in Q2 FY26.
9M FY26 consolidated PAT reached ₹1,028.34 million compared to ₹986.85 million in 9M FY25.

💡 Investors should view the strong sequential and year-on-year growth positively, especially the sharp recovery in margins compared to Q2. The stock remains attractive for those looking for growth in the CDMO and branded generics space, supported by a steady dividend payout.

Innova Captab Declares ₹2 Interim Dividend; Q3 Net Profit Rises 23% YoY to ₹421.5 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 01:08 PM

Innova Captab Limited reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, while EPS rose to ₹7.37 from ₹5.97 in the previous year's corresponding quarter. The Board has declared an interim dividend of ₹2 per equity share (20% of face value) with a record date of January 30, 2026. For the nine-month period ended December 2025, the company achieved a total income of ₹11,880.72 million.

Consolidated Revenue from operations surged 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Net Profit for the quarter stood at ₹421.49 million, up from ₹342.04 million in Q3 FY25.
Declared an interim dividend of ₹2 per equity share (20% of face value ₹10) for FY 2025-26.
Nine-month consolidated net profit reached ₹1,028.34 million compared to ₹986.85 million YoY.
Record date for the interim dividend is fixed as Friday, January 30, 2026.

💡 Investors may view the strong revenue growth and dividend declaration as a sign of healthy cash flows and operational scaling. The stock remains a key watch in the pharmaceutical CDMO space given its consistent earnings growth.

Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹4,503 Mn; Declares ₹2 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 01:05 PM

Innova Captab Limited reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations rising 42.3% YoY to ₹4,502.93 million. Net profit for the quarter grew 23.2% YoY to ₹421.49 million, showing a strong recovery from the previous quarter's ₹296.70 million. The Board also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. This growth is supported by the consolidation of subsidiaries including Sharon Bio-Medicine and Univentis Medicare.

Consolidated Revenue from Operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million from ₹342.04 million in the previous year.
Declared an interim dividend of ₹2 per equity share with a record date of January 30, 2026.
Quarter-on-quarter (QoQ) profit showed a significant jump of 42% from ₹296.70 million in Q2 FY26.
Finance costs increased to ₹39.50 million in Q3 FY26 compared to just ₹1.66 million in Q3 FY25.

💡 Investors should take note of the strong top-line growth and the company's ability to maintain dividend payouts. The significant QoQ recovery in margins is a positive sign, though rising finance costs warrant continued monitoring.

Innova Captab Schedules Q3 & 9M FY26 Earnings Call for January 27, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 19 Jan 2026, 06:48 PM

Innova Captab Limited has announced an earnings conference call scheduled for January 27, 2026, at 12:00 PM IST. The management will discuss the company's operational and financial performance for the third quarter and nine months ended December 31, 2025. Key attendees include Managing Director Vinay Lohariwala and CFO Lokesh Bhasin. This routine interaction provides a platform for analysts and institutional investors to seek clarifications on the latest financial results.

Earnings call set for January 27, 2026, at 12:00 Noon IST via virtual mode
Discussion to cover financial results for Q3 and 9M ended December 31, 2025
Senior management including MD and CFO will lead the interaction
Primary access numbers provided are +91 22 6280 1309 and +91 22 7115 8210

💡 Investors should monitor the call for updates on the company's expansion plans and margin performance. Reviewing the Q3 FY26 results prior to the call is recommended for informed participation.

Innova Captab Board to Meet Jan 23 for Q3 Results and Interim Dividend Consideration

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 19 Jan 2026, 03:16 PM

Innova Captab Limited has scheduled a board meeting on January 23, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider a proposal for declaring an interim dividend for the financial year 2025-26. If approved, the company has already fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. This dual announcement indicates potential cash returns to shareholders alongside the quarterly performance update.

Board meeting scheduled for January 23, 2026, to review Q3 and 9M FY26 financial performance.
Proposal for an interim dividend for FY 2025-26 to be considered during the meeting.
Record date for the potential interim dividend is fixed as January 30, 2026.
Trading window for insiders remains closed from January 1, 2026, until 48 hours after the results are declared.

💡 Investors should monitor the January 23 announcement for the dividend amount and earnings growth to assess the company's yield and operational health.

Innova Captab Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 01:01 PM

Innova Captab Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited (the Registrar and Share Transfer Agent), covers the period from October 1, 2025, to December 31, 2025. It confirms that the company received zero requests for dematerialization or rematerialization of shares during this quarter. This is a standard administrative filing required for all listed entities in India.

Compliance certificate submitted for the quarter ended December 31, 2025
Registrar KFin Technologies confirmed zero demat or remat requests during the period
The reporting period covered is from October 1, 2025, to December 31, 2025
Filing ensures adherence to SEBI (Depositories and Participants) Regulations, 2018

💡 No action is required as this is a routine regulatory filing with no impact on business fundamentals. Investors should monitor the company's upcoming quarterly financial results for performance insights.

View All INNOVACAP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The CDMO business grew 15% YoY in Q2 FY26 (INR 265.7 Cr) and 12% in H1 FY26 (INR 515.2 Cr). The Branded Generics business grew 31% YoY in Q2 FY26 (INR 114.6 Cr) and 43% in H1 FY26 (INR 216.7 Cr).

Geographic Revenue Split

Exports contributed 30% to the overall revenue mix in both Q2 FY26 and H1 FY26, reflecting a well-diversified geographical presence.

Profitability Margins

PAT margins were approximately 8% in Q2 FY26. Sharon Bio-Medicine (subsidiary) reported a profit after taxation of INR 23.18 Cr on revenue of INR 197.48 Cr for FY25.

EBITDA Margin

EBITDA margin was 14.7% in Q2 FY26 and 15.4% in H1 FY26. EBITDA grew 8% YoY to INR 56.1 Cr in Q2 FY26 and 17% YoY to INR 112.6 Cr in H1 FY26.

Capital Expenditure

The company raised INR 293.11 Cr (net of expenses) through an IPO in December 2023, utilized for debt reduction and funding a greenfield manufacturing unit at Kathua, Jammu.

Credit Rating & Borrowing

Long-term bank facilities (INR 389.38 Cr) are rated CARE A; Positive (outlook revised from Stable in Sept 2025). Short-term facilities (INR 20.00 Cr) are rated CARE A1.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) are the primary raw materials. Specific categories include Cephalosporin-related inputs.

Capacity Expansion

Operationalized a new greenfield manufacturing unit at Kathua, Jammu. The Cephalosporin plant in Baddi successfully passed a UK-MHRA inspection.

Raw Material Costs

API prices have been declining, which pressured CDMO revenue, though signs of price stabilization were noted in Q2 FY26.

Manufacturing Efficiency

Average utilization of working capital limits remained low at approximately 27% for the 12-month period ended June 2025.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth is driven by the operationalization of the Jammu plant, deepening engagement with 300+ global clients, expanding the product portfolio, and geographic diversification into markets like the UK and Ukraine.

Products & Services

Generic formulations, contract-based pharmaceutical formulations (CDMO), and branded generics.

Brand Portfolio

Innova Captab (Corporate Brand). Specific consumer brand names are not disclosed in available documents.

New Products/Services

Expansion of the Cephalosporin product line and new stability batches from the Jammu facility are expected to drive near-term scale-up.

Market Expansion

Targeting international markets following successful inspections by the UK-MHRA (United Kingdom) and SMDC (Ukraine).

🌍 External Factors

Industry Trends

The pharmaceutical industry is highly competitive and fragmented, with a shift toward stringent global quality standards and increased outsourcing to CDMOs.

Competitive Landscape

Characterized by a large number of small and big players in the generic and contract manufacturing space.

Competitive Moat

Moat is built on long-term client relationships, adherence to global quality standards (UK-MHRA), and a robust product pipeline.

Macro Economic Sensitivity

Sensitive to API price fluctuations and global regulatory standards for pharmaceutical manufacturing.

Geopolitical Risks

Exposure to international regulatory bodies like the UK-MHRA and Ukraine's SMDC for market access.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Drugs Control Act, 1950; The Narcotic Drugs and Psychotropic Substances Act, 1985; and GMP standards.

Environmental Compliance

The company has implemented an ESG Policy and filed its Business Responsibility and Sustainability Report (BRSR) for FY25 with no recorded non-compliance.